BRPI0907956A2 - Uso de ranolazina para o tratamento de doenças cardiovasculares - Google Patents

Uso de ranolazina para o tratamento de doenças cardiovasculares

Info

Publication number
BRPI0907956A2
BRPI0907956A2 BRPI0907956-4A BRPI0907956A BRPI0907956A2 BR PI0907956 A2 BRPI0907956 A2 BR PI0907956A2 BR PI0907956 A BRPI0907956 A BR PI0907956A BR PI0907956 A2 BRPI0907956 A2 BR PI0907956A2
Authority
BR
Brazil
Prior art keywords
ranolazine
treatment
cardiovascular disease
cardiovascular
disease
Prior art date
Application number
BRPI0907956-4A
Other languages
English (en)
Inventor
Whedy Wang
Ewa Prokopczuk
Luiz Belardinelli
Louis Lange
Markus Jerling
Andrew Wolff
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of BRPI0907956A2 publication Critical patent/BRPI0907956A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0907956-4A 2008-02-13 2009-02-12 Uso de ranolazina para o tratamento de doenças cardiovasculares BRPI0907956A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/030,468 US20090111826A1 (en) 2007-02-13 2008-02-13 Use of ranolazine for the treatment of cardiovascular diseases
PCT/US2009/033950 WO2009102886A1 (en) 2008-02-13 2009-02-12 Use of ranolazine for the treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
BRPI0907956A2 true BRPI0907956A2 (pt) 2015-08-04

Family

ID=40626660

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907956-4A BRPI0907956A2 (pt) 2008-02-13 2009-02-12 Uso de ranolazina para o tratamento de doenças cardiovasculares

Country Status (13)

Country Link
US (2) US20090111826A1 (pt)
EP (1) EP2252295A1 (pt)
JP (1) JP2011511844A (pt)
KR (1) KR20110013352A (pt)
AU (1) AU2009214639A1 (pt)
BR (1) BRPI0907956A2 (pt)
CA (1) CA2714301A1 (pt)
CO (1) CO6531499A2 (pt)
EA (1) EA201070918A1 (pt)
EC (1) ECSP10010464A (pt)
IL (1) IL207247A0 (pt)
MX (1) MX2010008433A (pt)
WO (1) WO2009102886A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
AU2003248558B8 (en) * 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
CA2689633A1 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
JP2012502047A (ja) * 2008-09-04 2012-01-26 ギリアード サイエンシーズ， インコーポレイテッド 心房細動を治療する方法
MX2011012140A (es) * 2009-05-14 2012-02-28 Gilead Sciences Inc Ranolazina para el tratamiento de problemas del snc.
MX2014000095A (es) * 2011-07-07 2014-05-28 Janssen Diagnostics Llc Método de análisis de trastornos cardiovasculares y usos del mismo.
JP2024537585A (ja) * 2021-09-27 2024-10-16 タスリー・ファーマシューティカル・グループ・カンパニー・リミテッド 心筋虚血の治療のための医薬組成物及びその製造方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
ES2177601T3 (es) * 1989-06-23 2002-12-16 Syntex Llc Ranolazina y pepeerazinas relacionadas para uso en el tratamiento de estados de choque. .
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US6541479B1 (en) * 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
US6897305B2 (en) * 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US20050245502A1 (en) * 1999-08-23 2005-11-03 Phoenix Biosciences Treatments for viral infections
US6734192B1 (en) * 1999-08-23 2004-05-11 Mp-1 Inc. Treatment of viral infections
US6803457B1 (en) * 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
NZ520780A (en) * 2000-02-18 2006-04-28 Cv Therapeutics Inc Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US20030220312A1 (en) * 2000-05-11 2003-11-27 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders
WO2002007716A2 (en) * 2000-07-21 2002-01-31 Cv Therapeutics, Inc. Method for treating angina
ATE357257T1 (de) * 2000-07-27 2007-04-15 Pharmacia Corp Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen
GB0028414D0 (en) * 2000-11-22 2001-01-03 Univ Leeds Flush preservation solution
IL147696A0 (en) * 2001-01-25 2002-08-14 Pfizer Prod Inc Combination therapy
US6423705B1 (en) * 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
EP1385548B1 (en) * 2001-01-26 2007-05-23 Schering Corporation Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US20050250676A1 (en) * 2001-11-19 2005-11-10 Aventis Pharma Deutschland Gmbh Method of activating insulin receptor substrate-2 to stimulate insulin production
US6958352B2 (en) * 2002-02-08 2005-10-25 Smithkline Beecham Corporation Compounds for inhibiting insulin secretion and methods related thereto
CN1911460A (zh) * 2002-02-15 2007-02-14 Cv医药有限公司 用于医用装置的聚合物涂层
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
AU2003248558B8 (en) * 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
WO2004079372A1 (en) * 2003-03-05 2004-09-16 Metabolex Inc. Methods and compositions for treating and diagnosing diabetes and related diseases involving beta-trp
AU2004248187A1 (en) * 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
US20050074425A1 (en) * 2003-07-02 2005-04-07 Polycord, Inc. Method for delivering polymerized therapeutic agent compositions and compositions thereof
US7060723B2 (en) * 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
ES2258365B1 (es) * 2003-10-03 2007-12-01 Lacer, S.A. Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos.
WO2005070126A2 (en) * 2004-01-08 2005-08-04 The Regents Of The University Of Colorado Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
CA2568134A1 (en) * 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
MX2007005367A (es) * 2004-11-09 2007-06-18 Cv Therapeutics Inc Uso de ranolazina en combinacion con por lo menos un agente de remodelacion para revertir la remodelacion ventricular izquierda en el tratamiento de la insuficiencia cardiaca.
MX2007008162A (es) * 2005-01-06 2007-07-24 Cv Therapeutics Inc Formulaciones farmaceuticas de liberacion prolongada que contienen ranolazina.
US20060205727A1 (en) * 2005-03-11 2006-09-14 Wayne Kaesemeyer Combination therapy for endothelial dysfunction, angina and diabetes
US20080153840A1 (en) * 2006-12-21 2008-06-26 Luiz Belardinelli Reduction of cardiovascular symptoms
EP2117549A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of coronary microvascular diseases
JP2010518171A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 非冠微小血管疾患の処置のためのラノラジンの使用
CA2678272A1 (en) * 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
JP2010528112A (ja) * 2007-05-31 2010-08-19 ギリアード・パロ・アルト・インコーポレイテッド 糖尿病を治療する方法
CA2689633A1 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide

Also Published As

Publication number Publication date
EA201070918A1 (ru) 2011-02-28
KR20110013352A (ko) 2011-02-09
EP2252295A1 (en) 2010-11-24
US20090111826A1 (en) 2009-04-30
CA2714301A1 (en) 2009-08-20
WO2009102886A1 (en) 2009-08-20
MX2010008433A (es) 2011-03-02
US20100035890A1 (en) 2010-02-11
AU2009214639A1 (en) 2009-08-20
ECSP10010464A (es) 2010-10-30
JP2011511844A (ja) 2011-04-14
CO6531499A2 (es) 2012-09-28
IL207247A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
NL301192I2 (nl) Finerenon en zijn zouten, solvaten en solvaten van de zouten daarvan
SMT201500206B (it) Composti spiro-ossindolici e loro uso come agenti terapeutici
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
BRPI0821668A2 (pt) Uso
SMT201500218B (it) Composti aril-fenil-solfonammido-cicloalchile e loro uso
SMT201500186B (it) Autoanticorpi umani anti-alfa-sinucleina
HRP20180718T1 (hr) Oligopeptidni spojevi i njihova upotreba
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
BRPI0822104A2 (pt) Composições antimicrobianas e métodos para o uso das mesmas
PT3812360T (pt) Compostos de monoclorotrifluoropropeno e composições e métodos utilizando os mesmos
EP2263545A4 (en) sonographer
BRPI0911849A2 (pt) protetores solares
BRPI0813670A2 (pt) Compostos para tratamento
EP2189118A4 (en) ULTRASOUND DEVICE
DK2173831T3 (da) Brøndbehandling
BRPI0912687A2 (pt) uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
BRPI1011036A2 (pt) uso
BRPI0915905A2 (pt) uso de derivados de pirimidilaminobenzamida para o tratamento de fibrose
BRPI0909223A2 (pt) uso de catepsaina c
IL207247A0 (en) Use of ranolazine for the treatment of cardiovascular disease
BRPI0909840A2 (pt) Uso de 4-tio-2-deoxinucleosídios
BRPI0822637A2 (pt) Uso de lanosta-8, 24-dien-3-óis
FI20085102L (fi) Probioottien uusi käyttö

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.